View Older Stories View More Recent Stories

May 25, 2022 03:00AM Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
May 24, 2022 06:46AM Pfizer (PFE) Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
May 24, 2022 06:45AM Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
May 23, 2022 06:45AM Pfizer (PFE) -BioNTech (BNTX) COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45AM Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45AM Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 17, 2022 11:40AM Pfizer (PFE), BioNTech (BNTX) Confirm EUA for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
May 17, 2022 11:40AM Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
May 10, 2022 06:55AM Pfizer (PFE) Acquires Biohaven Pharmaceuticals (BHVN) for $148.50/sh or $11.6B in Cash
May 10, 2022 06:45AM Pfizer to Acquire Biohaven Pharmaceuticals
May 6, 2022 06:45AM Myovant Sciences (MYOV) and Pfizer (PFE) Announce FDA Extended Review Period of sNDA for MYFEMBREE
May 6, 2022 06:45AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
May 6, 2022 06:45AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Apr 28, 2022 08:00AM Pfizer Declares Second-Quarter 2022 Dividend
Apr 27, 2022 06:45AM Pfizer (PFE) and Biohaven’s (BHVN) VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Apr 27, 2022 06:45AM Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Apr 26, 2022 06:45AM Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Apr 26, 2022 05:41AM Valneva SE (VALN) and Pfizer (PFE) Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Apr 26, 2022 01:00AM Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Apr 19, 2022 10:00AM Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
Apr 14, 2022 06:46AM Pfizer (PFE) and BioNTech SE (BNTX) Report Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children Aged 5-11
Apr 14, 2022 06:45AM Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Apr 12, 2022 05:43AM Myovant Sciences (MYOV) and Pfizer (PFE) Issues Update on sNDA for MYFEMBREE
Apr 12, 2022 12:00AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Apr 12, 2022 12:00AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Apr 11, 2022 06:46AM Pfizer (PFE) Names David M. Denton Chief Financial Officer
Apr 11, 2022 06:45AM Pfizer Names David M. Denton Chief Financial Officer
Apr 7, 2022 06:45AM Pfizer (PFE) to Acquire ReViral for Up to $525 Million
Apr 7, 2022 06:45AM Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Apr 7, 2022 06:45AM Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Mar 29, 2022 10:31AM Pfizer (PFE), BioNTech (BNTX) Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Mar 29, 2022 10:30AM  Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
Mar 29, 2022 06:45AM Pfizer (PFE) Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Mar 29, 2022 06:45AM Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Mar 24, 2022 06:45AM Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
Mar 24, 2022 06:45AM Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
Mar 23, 2022 06:46AM Pfizer (PFE) Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients Achieved Statistically Significant Improvements
Mar 23, 2022 06:45AM Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
Mar 22, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
Mar 22, 2022 06:45AM Pfizer (PFE) to Supply UNICEF up to 4M Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries
Mar 22, 2022 06:45AM Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries
Mar 17, 2022 07:31AM Alnylam Pharma (ALNY) Files Patent Infringement Suits against Pfizer (PFE) and Moderna (MRNA)
Mar 16, 2022 05:58AM Pfizer (PFE) and BioNTech (BNTX) Submit Request for US Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Mar 15, 2022 06:00PM Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Mar 11, 2022 08:35AM Pfizer (PFE) Completes Arena Pharmaceuticals Acquisition
Mar 11, 2022 08:34AM Pfizer Completes Acquisition of Arena Pharmaceuticals
Mar 9, 2022 06:45AM Pfizer (PFE) Commences Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
Mar 9, 2022 06:45AM Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
Mar 8, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Mar 8, 2022 06:16AM Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
View More Recent Stories View Older Stories